These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30639792)

  • 1. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
    Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
    Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients.
    Kashyap S; Singh MK; Kumar N; Jha J; Lomi N; Meel R; Bakhshi S; Sen S; Singh L
    Br J Ophthalmol; 2024 May; 108(6):903-912. PubMed ID: 36918273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.
    Stålhammar G; Seregard S; Grossniklaus HE
    Cancer Med; 2019 Jun; 8(6):2784-2792. PubMed ID: 30993893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.
    Lee SJ; Jun SY; Lee IH; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Yoon G; Kim JG
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1005-1014. PubMed ID: 29520442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer.
    Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
    Ann Surg; 2019 Jun; 269(6):1101-1108. PubMed ID: 31082908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of nm23-H1 in uveal melanoma.
    Bakalian S; Marshall JC; Faingold D; Logan P; Antecka E; Burnier MN
    Melanoma Res; 2007 Oct; 17(5):284-90. PubMed ID: 17885583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
    Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
    Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
    Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
    Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
    Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
    Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
    Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
    Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoints indoleamine 2,3-dioxygenase 1 and programmed death-ligand 1 in oral mucosal dysplasia.
    Sieviläinen M; Passador-Santos F; Almahmoudi R; Christopher S; Siponen M; Toppila-Salmi S; Salo T; Al-Samadi A
    J Oral Pathol Med; 2018 Sep; 47(8):773-780. PubMed ID: 29851145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
    Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
    Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
    Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
    EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.
    Rad Pour S; Morikawa H; Kiani NA; Yang M; Azimi A; Shafi G; Shang M; Baumgartner R; Ketelhuth DFJ; Kamleh MA; Wheelock CE; Lundqvist A; Hansson J; Tegnér J
    Sci Rep; 2019 Aug; 9(1):12150. PubMed ID: 31434983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
    Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
    Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
    Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
    J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
    Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E
    J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.
    Ishihara S; Yamada Y; Iwasaki T; Yoshimoto M; Toda Y; Kohashi K; Yamamoto H; Matsumoto Y; Nakashima Y; Oda Y
    Oncol Rep; 2021 Jan; 45(1):379-389. PubMed ID: 33155664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.